LAPTM4B and hepatocellular carcinoma: As AP4 could promote cell proliferation and metastasis but reduce chemotherapy sensitivity via LAPTM4B, we examined whether coexpression of AP4 and LAPTM4B could be treated as a prognostic marker in HCC patients.